Acumen Pharmaceuticals (ABOS) Operating Expenses (2020 - 2026)

Acumen Pharmaceuticals' Operating Expenses history runs 7 years deep, the most recent figure standing at $21.1 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 30.36% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $114.6 million (down 9.48% YoY), while the FY2025 annual figure was $123.8 million, up 8.61% from the prior year.
• Operating Expenses came in at $21.1 million for Q1 2026 at Acumen Pharmaceuticals, down from $25.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $41.8 million in Q2 2025 to a low of $9.2 million in Q1 2022.
• A 5-year average of $21.5 million and a median of $18.5 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 202.56% in 2022 and plunged 36.36% in 2025, its largest moves.
• Acumen Pharmaceuticals' Operating Expenses stood at $14.2 million in 2022, then grew by 29.74% to $18.5 million in 2023, then surged by 114.2% to $39.6 million in 2024, then tumbled by 36.36% to $25.2 million in 2025, then retreated by 16.07% to $21.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $21.1 million, $25.2 million, and $26.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison